LT2488203T - Išplitusios intravaskulinės koaguliacijos gydymo būdai, slopinant nuo masp-2 priklausomą komplemento aktyvinimą - Google Patents

Išplitusios intravaskulinės koaguliacijos gydymo būdai, slopinant nuo masp-2 priklausomą komplemento aktyvinimą

Info

Publication number
LT2488203T
LT2488203T LTEP10824223.1T LT10824223T LT2488203T LT 2488203 T LT2488203 T LT 2488203T LT 10824223 T LT10824223 T LT 10824223T LT 2488203 T LT2488203 T LT 2488203T
Authority
LT
Lithuania
Prior art keywords
methods
complement activation
intravascular coagulation
disseminated intravascular
dependent complement
Prior art date
Application number
LTEP10824223.1T
Other languages
English (en)
Inventor
Hans-Wilhelm Schwaeble
Thomas A. Dudler
Clark E. Tedford
James B. Parent
Gregory A. Demopulos
Original Assignee
Omeros Corporation
University Of Leicester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Omeros Corporation, University Of Leicester filed Critical Omeros Corporation
Publication of LT2488203T publication Critical patent/LT2488203T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21104—Mannan-binding lectin-associated serine protease-2 (3.4.21.104)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
LTEP10824223.1T 2009-10-16 2010-10-15 Išplitusios intravaskulinės koaguliacijos gydymo būdai, slopinant nuo masp-2 priklausomą komplemento aktyvinimą LT2488203T (lt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27927909P 2009-10-16 2009-10-16
US32272210P 2010-04-09 2010-04-09
PCT/US2010/052954 WO2011047346A1 (en) 2009-10-16 2010-10-15 Methods for treating disseminated intravascular coagulation by inhibiting masp-2 dependent complement activation

Publications (1)

Publication Number Publication Date
LT2488203T true LT2488203T (lt) 2017-05-25

Family

ID=43876603

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP10824223.1T LT2488203T (lt) 2009-10-16 2010-10-15 Išplitusios intravaskulinės koaguliacijos gydymo būdai, slopinant nuo masp-2 priklausomą komplemento aktyvinimą

Country Status (20)

Country Link
US (4) US8652477B2 (lt)
EP (2) EP2488203B1 (lt)
JP (2) JP5911804B2 (lt)
KR (2) KR101759895B1 (lt)
CN (2) CN102781471B (lt)
AU (1) AU2010306581B2 (lt)
BR (1) BR112012008970A2 (lt)
CA (2) CA2971474C (lt)
CY (1) CY1118696T1 (lt)
DK (1) DK2488203T3 (lt)
ES (1) ES2617920T3 (lt)
HU (1) HUE030897T2 (lt)
LT (1) LT2488203T (lt)
MX (2) MX354028B (lt)
NZ (2) NZ624065A (lt)
PL (1) PL2488203T3 (lt)
PT (1) PT2488203T (lt)
RU (1) RU2600876C2 (lt)
SI (1) SI2488203T1 (lt)
WO (1) WO2011047346A1 (lt)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8840893B2 (en) 2004-06-10 2014-09-23 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
EP2488203B1 (en) * 2009-10-16 2016-12-07 Omeros Corporation Methods for treating disseminated intravascular coagulation by inhibiting masp-2 dependent complement activation
AU2013201606B2 (en) * 2011-04-08 2016-02-25 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US9644035B2 (en) 2011-04-08 2017-05-09 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
JP5937197B2 (ja) 2011-04-08 2016-06-22 ユニバーシティー オブ レスター Ｍａｓｐ−２依存性補体活性化に関連した状態を治療するための方法
SI2704743T1 (sl) 2011-05-04 2020-08-31 Omeros Corporation Sestave za zaviranje sprožitve komplementov, odvisnih od masp-2
KR20200015952A (ko) * 2012-06-18 2020-02-13 오메로스 코포레이션 다양한 질환 및 장애의 치료를 위해 masp-1 및/또는 masp-2 및/또는 masp-3를 억제하는 조성물 및 방법
CN110818798A (zh) 2012-10-25 2020-02-21 美国比奥维拉迪维股份有限公司 抗补体C1s抗体和其用途
WO2014071206A1 (en) 2012-11-02 2014-05-08 True North Therapeutics, Inc. Anti-complement c1s antibodies and uses thereof
US20150017162A1 (en) * 2013-03-15 2015-01-15 Omeros Corporation Methods of Generating Bioactive Peptide-bearing Antibodies and Compositions Comprising the Same
BR112015023207A8 (pt) 2013-03-15 2018-01-23 Shire Viropharma Inc composições de ci-inh e métodos para prevenção e tratamento de desordens associadas à deficiência de inibidor de c1 esterase.
CN103454265A (zh) * 2013-08-09 2013-12-18 北京润诺思医疗科技有限公司 一种糖尿病预测标志物-纤维胶凝蛋白-3(Ficolin-3)化学发光定量检测试剂盒及其制备方法
ES2829913T3 (es) * 2013-10-17 2021-06-02 Omeros Corp Procedimientos de tratamiento de afecciones asociadas con la activación del complemento dependiente de MASP-2
RU2542401C1 (ru) * 2013-11-06 2015-02-20 Федеральное бюджетное учреждение науки "Московский научно-исследовательский институт эпидемиологии и микробиологии им. Г.Н. Габричевского" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека Способ определения функциональной активности компонента с2 комплемента человека
RU2542404C1 (ru) * 2013-11-06 2015-02-20 Федеральное бюджетное учреждение науки "Московский научно-исследовательский институт эпидемиологии и микробиологии им. Г.Н. Габричевского" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека Способ определения функциональной активности компонента с4 комплемента человека
WO2015187992A2 (en) * 2014-06-05 2015-12-10 The Regents Of The University Of Colorado, A Body Corporate Map44 polypeptides and constructs based on natural antibodies and uses thereof
NZ727420A (en) 2014-06-12 2018-06-29 Ra Pharmaceuticals Inc Modulation of complement activity
EP3988110A1 (en) 2015-01-28 2022-04-27 RA Pharmaceuticals, Inc. Modulators of complement activity
CN104688727A (zh) * 2015-03-24 2015-06-10 中国人民解放军第三军医大学 青蒿琥酯在制备治疗中晚期脓毒症药物中的运用
PL3280440T3 (pl) 2015-04-06 2023-06-19 Bioverativ Usa Inc. Humanizowane przeciwciała anty-c1s i sposoby ich zastosowania
RS64067B1 (sr) 2015-12-16 2023-04-28 Ra Pharmaceuticals Inc Modulatori aktivnosti komplementa
AU2017205453B2 (en) 2016-01-05 2020-03-12 Omeros Corporation Methods for inhibiting fibrosis in a subject in need thereof
JOP20170170B1 (ar) 2016-08-31 2022-09-15 Omeros Corp صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق
JOP20190068A1 (ar) * 2016-10-13 2019-04-01 Omeros Corp طرق لتقليل البول البروتيني في خاضع بشري يعاني من الاعتلال الكلوي a الناتج عن الجلوبيولين المناعي
CN108072761B (zh) * 2016-11-15 2020-03-17 中国科学院上海生命科学研究院 Masp-1在区分初发暴发性和经典1型糖尿病中的应用
MX2019006527A (es) 2016-12-07 2019-08-01 Ra Pharmaceuticals Inc Moduladores de la actividad del complemento.
HUP1700012A2 (en) 2017-01-06 2018-07-30 Evolveritas Kft Novel proteins and use thereof
CN110709103B (zh) * 2017-04-05 2024-02-02 机敏医药股份有限公司 用于生物学样品中具有改善的性能的timp2的测定法
BR112020010916A2 (pt) 2017-12-04 2020-11-17 Ra Pharmaceuticals, Inc moduladores da atividade do complemento
GB201800620D0 (en) 2018-01-15 2018-02-28 Univ Manchester C3b Binding Polypeptide
CN109360657B (zh) * 2018-09-27 2022-06-03 上海利连信息科技有限公司 一种医院感染数据的样本选取的时间段推理方法
GB2583560A (en) 2018-12-11 2020-11-04 Admirx Inc Fusion protein constructs for complement associated disease
WO2020185541A2 (en) 2019-03-08 2020-09-17 Ra Pharmaceuticals, Inc. Modulators of complement activity
EP3947352A1 (en) 2019-03-29 2022-02-09 RA Pharmaceuticals, Inc. Complement modulators and related methods
CN113710230A (zh) 2019-04-24 2021-11-26 Ra制药公司 用于调节补体活性的组合物和方法
CN115052862A (zh) 2019-12-04 2022-09-13 奥默罗斯公司 Masp-2抑制剂和使用方法
BR112022010895A2 (pt) 2019-12-04 2022-09-06 Omeros Corp Composto, composição farmacêutica, e, método para tratar uma doença ou distúrbio associado à serina protease-2 associada à lectina de ligação ao manan
AU2020395306A1 (en) 2019-12-04 2022-06-30 Omeros Corporation MASP-2 inhibitors and methods of use
CN115052604A (zh) 2019-12-04 2022-09-13 奥默罗斯公司 Masp-2抑制剂和使用方法
CN111956200B (zh) * 2020-09-01 2023-07-21 徐州利华电子科技发展有限公司 微循环高速血流测算系统和测算方法
CN114634575A (zh) * 2020-12-16 2022-06-17 康诺亚生物医药科技（成都）有限公司 一种补体抑制剂的开发和应用
KR20240116540A (ko) * 2021-12-10 2024-07-29 오메로스 코포레이션 Masp-2의 세린 프로테아제 도메인에 결합하는 치료 항체 및 이것의 용도
WO2023174039A1 (en) * 2022-03-18 2023-09-21 Inmagene Biopharmaceuticals (Hangzhou) Co., Ltd. Masp-2-targetting antibodies and uses thereof
WO2024069200A2 (en) 2022-09-29 2024-04-04 Evolveritas Biotechnológiai Korlátolt Felelősségű Társaság A modified protein scaffold and use thereof
WO2024118840A1 (en) 2022-11-30 2024-06-06 Omeros Corporation Fused pyrimidines as masp-2 inhibitors

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4394370A (en) 1981-09-21 1983-07-19 Jefferies Steven R Bone graft material for osseous defects and method of making same
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4526909A (en) 1984-01-09 1985-07-02 Regents Of The University Of California Polymethylmethacrylate delivery system for bone morphogenetic protein
US4563489A (en) 1984-02-10 1986-01-07 University Of California Biodegradable organic polymer delivery system for bone morphogenetic protein
JPH0662679B2 (ja) 1985-06-21 1994-08-17 新田ゼラチン株式会社 組織親和性コラ−ゲンとその製法
US5453566A (en) * 1986-03-28 1995-09-26 Calgene, Inc. Antisense regulation of gene expression in plant/cells
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
WO1989005852A1 (en) 1987-12-15 1989-06-29 Macphillamy Cummins & Gibson Ribozymes
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8822492D0 (en) 1988-09-24 1988-10-26 Considine J Apparatus for removing tumours from hollow organs of body
US5211657A (en) * 1988-11-07 1993-05-18 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Laminin a chain deduced amino acid sequence, expression vectors and active synthetic peptides
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5549910A (en) * 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
SG46445A1 (en) 1990-01-26 1998-02-20 Immunomedics Inc Vaccines against cancer and infectious diseases
JP3218637B2 (ja) 1990-07-26 2001-10-15 大正製薬株式会社 安定なリポソーム水懸濁液
US5789573A (en) 1990-08-14 1998-08-04 Isis Pharmaceuticals, Inc. Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2
JP2958076B2 (ja) 1990-08-27 1999-10-06 株式会社ビタミン研究所 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法
ES2206447T3 (es) * 1991-06-14 2004-05-16 Genentech, Inc. Anticuerpo humanizado para heregulina.
MX9304075A (es) * 1992-07-08 1994-04-29 Applied Research Systems Composicion farmaceutica para el tratamiento o profilaxis de los desordenes trombohemorragicos consuntivos.
IL108367A0 (en) 1993-01-27 1994-04-12 Hektoen Inst For Medical Resea Antisense polynzcleotide inhibition of human growth factor-sensitive cancer cells
US5801154A (en) 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
US5856121A (en) 1994-02-24 1999-01-05 Case Western Reserve University Growth arrest homebox gene
JPH07238100A (ja) 1994-02-25 1995-09-12 Sumitomo Electric Ind Ltd ヒトのｍａｓｐに対するモノクローナル抗体
US5741516A (en) 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
JPH0867636A (ja) * 1994-08-30 1996-03-12 Yamanouchi Pharmaceut Co Ltd 播種性血管内凝固症候群（ｄｉｃ）の予防治療薬
US6492332B1 (en) 1995-12-12 2002-12-10 Omeros Corporation Irrigation solution and methods for inhibition of tumor cell adhesion, pain and inflammation
US5795587A (en) * 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5738868A (en) 1995-07-18 1998-04-14 Lipogenics Ltd. Liposome compositions and kits therefor
BR9509985A (pt) * 1995-12-12 1998-11-03 Omeros Med Sys Inc Solução para irrigação e método para inibição de dor inflamação e esparmo
US5739119A (en) 1996-11-15 1998-04-14 Galli; Rachel L. Antisense oligonucleotides specific for the muscarinic type 2 acetylcholine receptor MRNA
US6969601B2 (en) * 1997-04-03 2005-11-29 Jensenius Jens Chr MASP-2, a complement-fixing enzyme, and uses for it
US6297024B1 (en) * 1998-10-15 2001-10-02 Cell Activation, Inc. Methods for assessing complement activation
US7273925B1 (en) * 1998-12-15 2007-09-25 Brigham And Women's Hospital, Inc. Methods and products for regulating lectin complement pathway associated complement activation
CA2347734A1 (en) 1998-12-15 2000-06-22 Brigham And Women's Hospital, Inc. Methods and products for regulating lectin complement pathway associated complement activation
US6235494B1 (en) * 1999-02-08 2001-05-22 The Scripps Research Institute Substrates for assessing mannan-binding protein-associated serine protease activity and methods using the substrates
KR20020012320A (ko) 1999-07-21 2002-02-15 그레고리 에이. 데모풀로스 동통, 염증 및 연골 퇴화를 억제하기 위한 용액 및 억제방법
JP2003507338A (ja) 1999-08-13 2003-02-25 ザ ブリグハム アンド ウイメンズ ホスピタル インコーポレイテッド レクチン補体経路（ｌｃｐ）のインヒビターおよびその使用
WO2001040451A2 (en) * 1999-12-02 2001-06-07 Jens Christian Jensenius Masp-3, a complement-fixing enzyme, and uses for it
US6649592B1 (en) * 2000-01-14 2003-11-18 Science & Technology Corporation @ Unm Peptide inhibitors of LFA-1/ICAM-1 interaction
DK2026073T3 (en) * 2000-04-29 2016-07-25 Univ Iowa Res Found Diagnosis and treatment of macular degeneration-related disorders
SG98393A1 (en) 2000-05-19 2003-09-19 Inst Materials Research & Eng Injectable drug delivery systems with cyclodextrin-polymer based hydrogels
CA2415751C (en) * 2000-07-13 2015-06-16 Steffen Thiel Masp-2, a complement-fixing enzyme, and uses for it
US20020094332A1 (en) * 2001-01-18 2002-07-18 Alexion Pharmaceuticals Method of prophylaxis against large myocardial infractions
CA2454562A1 (en) 2001-07-26 2003-02-06 Alexion Pharmaceuticals, Inc. Method of improving cognitive function
EP1467801A1 (en) 2002-01-22 2004-10-20 Alexion Pharmaceuticals, Inc. Method of prophylaxis against large myocardial infarctions
WO2003063799A2 (en) 2002-02-01 2003-08-07 Omeros Corporation Compositions and methods for systemic inhibition of cartilage degradation
US20050221382A1 (en) 2002-03-18 2005-10-06 Rother Russell P Stratification of patient populations having or suspected of having rheumatoid arthritis
US7538195B2 (en) * 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
CN100519643C (zh) 2002-07-19 2009-07-29 奥默罗斯公司 可生物降解的三嵌段共聚物,它们的合成方法和从它制得的水凝胶和生物材料
AU2003261304A1 (en) 2002-07-30 2004-02-16 Omeros Corporation Ophthalmologic irrigation solutions and method
EP1545611B1 (en) 2002-09-06 2016-11-09 Alexion Pharmaceuticals, Inc. Method of treatment of asthma using antibodies to complement component c5
US20060275764A1 (en) * 2002-12-03 2006-12-07 Aarhus Universitet Method for determining predisposition to manifestation of immune system related diseases
US7361339B2 (en) * 2003-01-09 2008-04-22 Alexion Pharmaceuticals, Inc. Methods for reducing morality associated with acute myocardial infarction
EP2422812A1 (en) 2003-02-21 2012-02-29 Genentech, Inc. Methods for preventing and treating tissue damage associated with ischemia-reperfusion injury
CA2519258C (en) * 2003-03-17 2014-04-22 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Construct comprising region recognized by antibody against von willebrand factor-specific cleaving protease
EP2374819B1 (en) 2003-05-12 2017-03-22 Helion Biotech ApS Antibodies to MASP-2
WO2005014849A2 (en) * 2003-07-03 2005-02-17 Euro-Celtique, S.A. Genes associated with responses to neuropathic pain
US7482376B2 (en) * 2003-07-03 2009-01-27 3-Dimensional Pharmaceuticals, Inc. Conjugated complement cascade inhibitors
EP1670910A1 (en) 2003-09-05 2006-06-21 Natimmune A/S Masp-2 crystal structure and uses thereof
US20050169921A1 (en) * 2004-02-03 2005-08-04 Leonard Bell Method of treating hemolytic disease
US7919094B2 (en) * 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
LT2465534T (lt) * 2004-06-10 2017-07-25 Omeros Corporation Ligų, susijusių su nuo masp-2 priklausomu komplemento aktyvavimu, gydymo būdai
US20060018896A1 (en) * 2004-06-10 2006-01-26 University Of Leicester Methods for treating conditions associated with lectin-dependent complement activation
GB0412966D0 (en) 2004-06-10 2004-07-14 Univ Leicester Genetically modified non-human mammals and cells
DK1902141T3 (da) * 2005-06-17 2012-05-07 Baxter Int ADAMTS 13-holdige sammensætninger med thrombolytisk virkning
CA2640167A1 (en) * 2006-01-27 2007-08-02 Rappaport Family Institute For Research In The Medical Sciences Methods and kits for determining blood coagulation
AU2010264520A1 (en) * 2009-06-23 2012-01-19 Alexion Pharmaceuticals, Inc. Bispecific antibodies that bind to complement proteins
EP2488203B1 (en) * 2009-10-16 2016-12-07 Omeros Corporation Methods for treating disseminated intravascular coagulation by inhibiting masp-2 dependent complement activation

Also Published As

Publication number Publication date
RU2600876C2 (ru) 2016-10-27
CA2971474A1 (en) 2011-04-21
KR20120099680A (ko) 2012-09-11
US8652477B2 (en) 2014-02-18
EP2488203B1 (en) 2016-12-07
HUE030897T2 (en) 2017-06-28
KR101759895B1 (ko) 2017-07-20
EP3150635A2 (en) 2017-04-05
WO2011047346A1 (en) 2011-04-21
CN106390117A (zh) 2017-02-15
CY1118696T1 (el) 2017-07-12
ES2617920T3 (es) 2017-06-20
SI2488203T1 (sl) 2017-07-31
KR20170086131A (ko) 2017-07-25
CA2777845C (en) 2017-08-01
CA2777845A1 (en) 2011-04-21
AU2010306581A1 (en) 2012-05-10
US20180291112A1 (en) 2018-10-11
CN102781471A (zh) 2012-11-14
CN102781471B (zh) 2016-10-12
CA2971474C (en) 2022-11-22
JP5911804B2 (ja) 2016-04-27
KR101788040B1 (ko) 2017-10-19
AU2010306581A2 (en) 2012-05-10
US20140205598A1 (en) 2014-07-24
PL2488203T3 (pl) 2017-08-31
EP3150635A3 (en) 2017-06-21
RU2012118506A (ru) 2013-11-27
NZ599906A (en) 2014-05-30
JP2013508301A (ja) 2013-03-07
EP2488203A1 (en) 2012-08-22
US20170233494A1 (en) 2017-08-17
US20110091450A1 (en) 2011-04-21
JP2015063567A (ja) 2015-04-09
AU2010306581B2 (en) 2015-03-19
MX354028B (es) 2018-02-08
NZ624065A (en) 2015-10-30
MX344322B (es) 2016-12-13
BR112012008970A2 (pt) 2019-12-10
EP2488203A4 (en) 2013-08-14
PT2488203T (pt) 2017-03-10
DK2488203T3 (en) 2017-03-13
MX2012004343A (es) 2012-05-22

Similar Documents

Publication Publication Date Title
PL2488203T3 (pl) Sposoby leczenia rozsianego wykrzepiania wewnątrznaczyniowego przez hamowanie aktywacji dopełniacza zależnej od masp-2
HK1250342A1 (zh) 用於治療與masp-2依賴性補體活化相關的狀況的方法
EP2432476A4 (en) METHOD FOR THE TREATMENT OR PREVENTION OF EYE DISEASES
DK3067067T3 (en) Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation
EP2252148A4 (en) METHOD FOR THE TREATMENT OF DARM DISEASES
GB201015794D0 (en) Soil treatment process
EP2611765A4 (en) METHODS OF TREATING NEURODEGENERATIVE DISEASES
EP2365747A4 (en) METHODS OF TREATING GASTROINTESTINAL DISEASES
IL209216A0 (en) Methods for preventing and treating neurodegenerative diseases
EP2341936A4 (en) METHOD FOR TREATING OR PREVENTING IL-1ß-CONTAINED ILLNESSES
PT2403503T (pt) Métodos para tratar doenças inflamatórias oculares
IL217492A0 (en) Treatment method
EP2453896A4 (en) PROCESS FOR TREATING SCHIZOPHRENIA
EP2688402A4 (en) METHODS FOR THE TREATMENT OR PREVENTION OF UROLOGIC INFLAMMATION
HRP20181116T1 (hr) Koncentrati za tretiranje supstrata
PL2516716T3 (pl) Sposób obróbki prania
IL209947A (en) Compounds for the treatment of corneal inflammation
EP2237777A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES
EP2427052A4 (en) METHODS AND COMPOSITIONS FOR USE IN THE TREATMENT OF OPHTHALMIC DISORDERS
GB2496723B (en) Sludge treatment process
AP2012006279A0 (en) Method for treating waste.
EP2278982A4 (en) COMPOSITIONS AND METHODS OF TREATING NEURODEEGENERATIVE ILLNESSES
GB0921303D0 (en) Treatment process
GB0916249D0 (en) Polymer treatment method
GB0914373D0 (en) Treatment method